Different MoDels of frailty in PreDeMentia anD DeMentia synDroMes

dementia is an increasingly common disease in the aging population, and the numbers are expected to rise exponentially in coming years. therefore, there is a critical need to potentially individualize new strategies able to prevent and to slow down the progression of predementia and dementia syndromes. despite a substantial increase in the epidemiological and clinical evidence on frailty, there is no consensus on its definition or on what criteria should be used to identify older individuals with frailty. Frailty appears to be a nonspecific state of vulnerability, which reflects multisystem physiological change. in fact, current thinking is that not only physical but also psychological, cognitive and social factors contribute to this multidimensional syndrome and need to be taken into account in its definition and treatment. cognition has already been considered as a component of frailty, and it has been demonstrated that it is associated with adverse health outcomes. in a recent populationbased study, physical frail demented patients were at higher risk of all-cause mortality over 3- and 7-year followup periods. Several studies have also reported that physical frailty is associated with low cognitive performance, incidence of alzheimer’s disease (ad), and mild cognitive impairment, and ad pathology in older persons with and without dementia. Most frailty instruments use a dichotomous scoring system classifying a person as either frail or not frail, while a continuous or an ordinal scoring system on multiple levels would be preferable to be used as an outcome measure. recently, a Multidimensional Prognostic index (MPi), derived from a standardized comprehensive geriatric assessment, was effective in predicting short- and long-term mortality risk in hospitalized patients with dementia. overall taken together these findings supported the concept that outcome measures linked to multidimensional impairment may be extremely important in making clinical decisions, especially for monitoring drug treatment in randomized clinical trials also for predementia and dementia syndromes.